Clinical Trials on Severe Thermal Injury, Greater Than 20% TBSA in New Zealand
Total 0 results
Nothing found
Sponsors and Collaborators
- EULAR Lupus Nephritis Trial Network Study Group
- Metiv Israel Psychotrauma Center
- Italian Academy of Rhinology
- Permanente Dental Associates Group, Oregon
- Spital Linth
- Azienda Sanitaria Locale N.1 dell'Umbria
- Hospital of Southern Jutland
- University of Crete Medical School - University Hospital of Heraklion
- Institute of Child Health, London, England
- Iran Ministry of Health, Treatment, and Medical Education
- Kevin W Hatton, MD, PhD
- INESC TEC - Institute for Systems and Computer Engineering, Technology and Science (Porto, Portugal)
- Skin Laser & Surgery Specialists
- Daily Centre for Psychiatry and Speech Disorders Poland
- Child Medical Center, 3 Rue de la Prugne, 63540 Romagnat, France
- Meng Li
- North Tees and Hartlepool NHS Foundation Trust
- Emergency Medical Service Ostrava, Ostrava, Czech Republic
- Amy Farabaugh, PhD
- Anthony Johnson
- View Full List
Medical Conditions
- Indirect Incentive
- Leiomyomas
- Haematologic Disease
- Relapsed/Refractory Large B-cell Lymphoma
- Management of Lung Cancer Patients
- Thyroid Eye Disease
- Laxative Compatibility
- Primary Lymphoma of the Central Nervous System
- Exercise Intolerance, Riboflavin-Responsive
- Sodium Selenite
- Mastoid Cavity
- Crystal Meth Addiction
- Peptic Ulcer With Haemorrhage
- Neuralgia, Postherpetic
- Tendon CSA
- Metformin Concentration
- Working Memory Training
- Post-micturition Incontinence
- Peripheral T-cell Lymphomas
- Non-small Cell Lung Cancer Stage ⅢA
- View Full List
Drug Interventions
- 5.0g SRT501
- Nicoderm C-Q Transdermal Product
- Cetuximab
- Tenofovir
- PCO371
- Anastrozole
- Modified Bolus 5-FU/LV with Irinotecan
- Percutaneous sirolimus
- 6-Mercaptopurine
- Sipuleucel-T
- Granulocyte colony-stimulating factor
- Tranexamic acid
- Amisulpride Oral Tablet
- Visanne (Dienogest, BAY86-5258)
- Follitropin beta liquid formulation
- Sodium Nitroprusside
- Vinorelbine tartrate
- Trastuzumab in combination with SubQ GM-CSF
- 30 mg CVL-231 as slow-release MR formulation
- Ketamine 0.3 mg/kg at anesthesia induction
- View Full List
CROs by country
- Contract Research Organizations in Armenia
- Contract Research Organizations in Azerbaijan
- Contract Research Organizations in Bangladesh
- Contract Research Organizations in El Salvador
- Contract Research Organizations in Kenya
- Contract Research Organizations in Madagascar
- Contract Research Organizations in Malta
- Contract Research Organizations in Pakistan
- Contract Research Organizations in Qatar
- Contract Research Organizations in Slovakia
- Contract Research Organizations in South Africa
- Contract Research Organizations in Sweden
- Contract Research Organizations in United Arab Emirates
- CRO list by country